Fri, 21 Mar 2014
With equity exposure and low initial-contribution limits, these analyst-vetted names could be a better choice.
After a period of relative calm, the Italian elections and fight over the sequester underscore some of the structural problems facing the global economy; investors should be prepared for volatility, says Morningstar's Jeremy Glaser .
Although the two office-supplies companies could realize meaningful cost synergies, the combined firm would still face enormous competitive pressures, says Morningstar's Liang Feng.
Moat trend, valuation, and stewardship all were large factors in StockInvestor editor Matt Coffina's recent adjustments to the Tortoise and Hare portfolios.
Five stats from the market and the stories behind them. This week: Fed's $40 billion bond buys in question, Wal-Mart's worrisome 1% same-store sales growth, and more.
Morningstar's Elizabeth Collins discusses the index's selection process and highlights one of the recent additions.
Morningstar recently upgraded several companies' moat ratings, and global equity research director Heather Brilliant explains why.
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Pharmaceutical firms' adept handling of patent expirations has boosted investors' opinions of the sector, says Morningstar's Damien Conover.
These management teams should be good stewards of shareholder capital in today's uncertain environment.
Widening investment-grade credit spreads and rising interest rates lead to losses.
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.
In an overall fairly valued market, it's time to be selective.
©2014 Morningstar Advisor. All right reserved.